Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,635 | 0,720 | 12:50 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | LakeShore Biopharma faces Nasdaq delisting after failing to meet bid price rule | 2 | Investing.com | ||
Fr | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq | 746 | PR Newswire | BEIJING, Sept. 12, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
10.09. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
10.09. | LakeShore Biopharma appoints advisors to evaluate buyout proposal | 1 | Investing.com | ||
29.08. | LakeShore Biopharma Board Reviewing Revised $0.86-Per-Share Buyout Proposal | - | RTTNews | ||
28.08. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
LAKESHORE BIOPHARMA Aktie jetzt für 0€ handeln | |||||
28.08. | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee | 442 | PR Newswire | BEIJING, Aug. 28, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
18.08. | LakeShore Biopharma receives $0.86/share buyout proposal from Oceanpine Capital | 2 | Seeking Alpha | ||
18.08. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
18.08. | Oceanpine Capital unterbreitet Übernahmeangebot für LakeShore Biopharma zu 0,86 US-Dollar je Aktie | 1 | Investing.com Deutsch | ||
18.08. | Oceanpine Capital proposes to acquire LakeShore Biopharma for $0.86 per share | 1 | Investing.com | ||
18.08. | LakeShore Biopharma Receives Proposal Letter From Oceanpine Capital | 1 | RTTNews | ||
18.08. | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company | 126 | PR Newswire | BEIJING, Aug. 18, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
01.08. | LakeShore Biopharma GAAP EPS of -RMB5.22, revenue of RMB615M | 1 | Seeking Alpha | ||
31.07. | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Fiscal Year 2025 Financial Results | 61 | PR Newswire | Total revenue reached RMB615.0 million, representing 7.2% year-over-year growth
Gross profit rose to RMB507.2 million, up 11.3% year-over-year
Gross margin improved... ► Artikel lesen | |
31.07. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
31.07. | LakeShore Biopharma Co., Ltd. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
15.07. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
08.07. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
08.07. | LakeShore Biopharma announces $15M private placement financing | 1 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SUMMIT THERAPEUTICS | 18,090 | 0,00 % | Summit Therapeutics stock rating reiterated at Buy by H.C. Wainwright | ||
MINERALYS THERAPEUTICS | 37,290 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
CG ONCOLOGY | 37,510 | 0,00 % | Hedge Fund and Insider Trading News: Ray Dalio, Warren Buffett, Bill Ackman, Dan Loeb, Arrowpoint Investment Partners, CG Oncology Inc (CGON), Tesla Inc (TSLA), and More | ||
SCISPARC | 4,365 | 0,00 % | Morning Market Movers: SciSparc, HIND, SQFT, FGNX See Big Swings | BEIJING (dpa-AFX) - At 7:55 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
EVOTEC | 6,252 | +0,61 % | EQS-NVR: Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Evotec SE
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem... ► Artikel lesen | |
LENZ THERAPEUTICS | 42,230 | 0,00 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
PRAXIS PRECISION MEDICINES | 44,030 | 0,00 % | Praxis Precision Medicines: Piper Sandler bestätigt "Overweight" nach positiven Studiendaten | ||
JANUX THERAPEUTICS | 23,460 | 0,00 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
BEAM THERAPEUTICS | 22,470 | 0,00 % | Fortschritte in der Pipeline: H.C. Wainwright bestätigt "Buy"-Rating für Beam Therapeutics | ||
PHATHOM PHARMACEUTICALS | 11,000 | 0,00 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
KINIKSA PHARMACEUTICALS | 35,430 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 40,060 | 0,00 % | Roth/MKM initiates Avidity Biosciences stock with Buy rating on platform potential | ||
RECURSION PHARMACEUTICALS | 4,720 | 0,00 % | What Analysts Are Saying About Recursion Pharmaceuticals Stock | ||
TOURMALINE BIO | 47,695 | 0,00 % | BMO Capital downgrades Tourmaline Bio stock rating following Novartis acquisition news | ||
STRUCTURE THERAPEUTICS | 21,620 | 0,00 % | JMP bestätigt Rating für Structure Therapeutics nach positiven Sicherheitsdaten |